Vaccine adjuvants - Current status and prospects on controlled release adjuvancity

Saudi Pharmaceutical Journal

Volumn 19, Issue 4, 2011, Pages 197-206

  Sivakumar, S M ^a   Safhi, Mohammed M ^a   Kannadasan, M ^b   Sukumaran, N ^c  

^a JAZAN UNIVERSITY   (Saudi Arabia)

^b DR B R AMBEDKAR UNIVERSITY   (India)

^c VELS INSTITUTE OF SCIENCE   (India)

Author keywords

Adjuvant and its types; Biodegradable polymers; Immune response; Microparticles; Vaccine delivery

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SALT; BACTERIAL TOXIN; CALCIUM PHOSPHATE; CALCIUM SALT; CARBOHYDRATE; CEREVARIX; CHITOSAN; DIPHTHERIA TOXIN; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INULIN; ISCOM; LIPOSOME; MICROSPHERE; MIFAMURTIDE; MINERAL OIL; PHOSPHORYL LIPID A; POLYGLACTIN; POLYLACTIC ACID; QUIL A; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTIBODY TITER; BACTERIAL CELL WALL; CARCINOGENIC ACTIVITY; CELLULAR IMMUNITY; CONTACT ALLERGY; CONTROLLED RELEASE FORMULATION; COST EFFECTIVENESS ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ERYTHEMA; ESCHERICHIA COLI; GRANULOMA; HEALTH PROGRAM; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLAMMATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; REVIEW; SUBCUTANEOUS NODULE; TH1 CELL; TH2 CELL; VACCINATION; VIBRIO CHOLERAE; VIRUS LIKE AGENT; WORLD HEALTH ORGANIZATION;

EID: 80052948179     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2011.06.003     Document Type: Review

References (96)

1. Achal P., Nicholas M.V., Jerry B.U. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 2005, 11(4):S63-S68.
2. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25:3752-3762.
3. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
4. Allison A.C., Byars N.E. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 1991, 28(3):279-284.
5. Allison A.C., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252-258.
6. Ambrosch F., Wiedermann G., Jonas S., Althaus B., Finkel B., Glück R., Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15(11):1209-1213.
7. Amiji M.M. Permeability and blood compatibility properties of chitosan-poly(ethylene oxide) blend membranes for haemodialysis. Biomaterials 1995, 16(8):593-599.
8. Antonis A.F.G., Bruschke C.J.M., Rueda P., Maranga L., Casal J.I., Vela C., Hilgers L.A.Th., Peter B.G.M.B., Weerdmeester K., Manuel J.T.C., Jan P.M.L. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006, 24:5481-5490.
9. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 2002, 1(1):111-118.
10. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 1993, 14(6):281-284.
11. Austin P.E., Dunn K.A., Elly-Cofield K., Brown C.K., Wooden W.A., Bradfield J.F. Subcuticular sutures and the rate of inflammation in non-contaminated wounds. Ann. Emerg. Med. 1995, 25(3):328-330.
12. Bandowiski M.K., Clark K., Bena Cerraf B., Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophases. Proc. Natl. Acad. Sci. USA 1993, 90(11):4942-4946.
13. Baylor N.W., Egan W., Richman P. Aluminum salt in vaccines - US perspective. Vaccine 2002, 20:S18-S23.
14. Byars, N.E., Allison, A.C., 1990. Immunologic adjuvants: general properties, advantages, and limitations. In: Zola, H. (Ed.), Laboratory Methods in Immunology. pp. 39-51.
15. Cleland J.L. Single administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 1999, 17(1):25-29.
16. Clements C.J., Griffth E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002, 20(Suppl. 3):S24-S33.
17. Cooper P.D. Vaccine adjuvants based on gamma inulin. Vaccine Design: The Subunit and Adjuvant Approach 1995, 559-580. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
18. Cooper P.D., Steele E.J. Algammulin: a new vaccine adjuvant comprising gamma inulin particles containing alum, preparation and in vitro properties. Vaccine 1991, 9(5):351-357.
19. Cooper P.D., McComb C., Steele E.J. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 1991, 9(6):408-415.
20. Dalsgaard K. A study of the isolation and characterization of the saponin Quil A. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and-mouth disease. Acta Vet. Scand. 1978, 69:1-40.
21. Dalsgaard K., Hilgers L., Trouve G. Classical and new approaches to adjuvant use in domestic food animals. Adv. Vet. Sci. Comp. Med. 1990, 35:121-160.
22. Davenport F.M. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 1968, 26(6):288-292.
23. Dell K., Koesters R., Linnebacher M., Klein C., Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 2006, 24(13):2238-2247.
24. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nat. Immunol. 2006, 7:449-455.
25. Donald Owens E., Nicholas Peppas A. Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
26. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 1980, 2(3):370-383.
27. Falo L.D., Bankowski M.K., Thompson K., Rock K.L. Targeting antigen in to phagocytic pathway in vivo induces protective tumor immunity. Nat. Med. 1995, 1(7):649-653.
28. Feng L., Qi X.R., Zhou X.J., Maitani Y., Wang S.C., Jiang Y., Nagai T. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release 2006, 112(1):35-42.
29. Fiore A.E., Bridges C.B., Cox N.J. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 2009, 333:43-82.
30. Freund J. The mode of action of immunological adjuvants. Adv. Tuberc. Res. 1956, 7:130-148.
31. Freund J., Thomson K.J., Hough H.B., Sommer H.E., Pisani T.M. Antibody formation and sensitization with the aid of adjuvants. J. Immunol. 1948, 60:383-398.
32. Freunds J., Casals J., Hosmer E.P. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 1937, 37:509-513.
33. Glenney A.T., Pope C.G., Waddington H., Wallace U. XXIII-the antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 1926, 29:38-39.
34. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11(3):293-306.
35. Gupta R.K., Roast B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds. Vaccine Design: The Subunit and Adjuvant Approach 1995, 229-248. Plenum Publishing Corporation, New York. M.F. Powell, M.F. Newman (Eds.).
36. Hanes J., Cleland J.L., Langer R. New advances in microsphere-based single-dose vaccines. Adv. Drug Deliv. Rev. 1997, 28:97-119.
37. Heath T.D., Edwards D.C., Ryman B.E. The adjuvant properties of liposomes. Biochem. Soc. Trans. 1976, 4:49-52.
38. Heufler C., Koch F., Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 1988, 167(2):700-705.
39. Hilleman M.R. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000, 18:1436-1447.
40. Hilleman M.R., Woodhour A.F., Friedman A., Phelps A.H. Studies for safety of adjuvant 65. Ann. Allergy 1972, 30(8):477-483.
41. Hobe K., Janssen E., Bentler B. The interface between innate and adaptive immunity. Nat. Immunol. 2004, 5:971-974.
42. Iezzi G., Karjalainen K., Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998, 8(1):89-95.
43. Ito M., Ban A., Ishihara M. Anti-ulcer effects of chitin and chitosan, healthy foods, in rats. Jpn. J. Pharmacol. 2000, 82(3):218-225.
44. Kane M.A. Status of hepatitis B immunization programme in 1998. Vaccine 1998, 16(S):S104-S108.
45. Kensil C.R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13:1-55.
46. Kensil C.R., Wu J.-Y., Soltysik S. Structural and immunological characterization of vaccine adjuvant QS-21. Vaccine Design: The Subunit and Adjuvant Approach 1995, 525-541. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
47. Kristmundsdoittr T., Ingvarsdottir K., Semundsdottir G. Chitosan matrix tablets: the influence of excipients on drug release. Drug Dev. Ind. Pharm. 1995, 21(13):1591-1598.
48. Le Moignic, Piony Application to man of vaccines consisting of emulsions in fatty substances (lipo-vaccines). Compt. Rend. Soc. Biol. 1916, 29:352-358.
49. Levie K., Gjorup I., Skinhoj P., Stoffel M. A 2-dose regimen of recombinant hepatitis B vaccine with the immune stimulant ASO4 compared with the standard 3-dose regimen of Energix-B in healthy young adults. Scand. J. Infect. Dis. 2002, 34(8):610-614.
50. Lofthouse S. Immunological aspects of controlled antigen delivery. Adv. Drug Deliv. Rev. 2002, 54(6):863-870.
51. Maria Alonso J., Sanchez A., Villamayor B., Guo Y., McIver J. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microsphere. Int. J. Pharm. 1999, 185(2):255-266.
52. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10(2):75-88.
53. Men Y., Thomasin C., Merkle H.P., Gander B., Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 1995, 13(7):683-709.
54. Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T., Mills K.H. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995, 13(18):1741-1749.
55. Morein B., Sundquist B., Hoglud S., Dalsgaard K., Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308:457-460.
56. Murray R., Cohen P., Hardegree M.C. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy 1972, 30(3):146-151.
57. Nagel J., Svec D., Waters T., Fireman P. IgE synthesis in man. I. Development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J. Immunol. 1977, 118:334-341.
58. Nixon D.F., Hioe C., Chen P.D., Bian Z., Kuebler P., Li M.L., Qiu H., Li X.M., Singh M., Richardson J., McGee P., Zamb T., Koff W., Wang C.Y., O'Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996, 14(16):1523-1530.
59. O'Hagan D.T., Wack A., Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin. Pharmacol. Ther. 2007, 82(6):740-744.
60. Owis M., Gupta C.M. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur. J. Biochem. 2000, 267(13):3946-3956.
61. Peris I., Langer R.S. A single-step immunization by sustained antigen release. J. Immunol. Methods 1979, 28(1-2):193-197.
62. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 2004, 82:482-496.
63. Pihlajamaki H., Bostman O., Hirvensalo E., Tormala P., Rokkanen P. Absorbable pins of self-reinforced poly-l-lactic acid for fixation of fractures and osteotomies. J. Bone Joint Surg. Br. 1992, 74(6):853-857.
64. Potter M., Boyce C.R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 1962, 193:1086-1087.
65. Ramon G. Sur 1'augmentation anormale de 1' antitoxine chez les chevaux producteurs de serum antidiphterique. Bull. Soc. Centr. Med. Vet. 1925, 101:227-234.
66. Ramon G. Procedes pour accroitre la production des antitoxins. Ann. Inst. Pasteur. 1926, 40:1-10.
67. Relyveld E.H. Preparation and use of calcium phosphate adsorbed vaccines. Dev. Biol. Stand. 1986, 65:131-136.
68. Relyveld E.H., Ickovic M.R., Henocq E., Garcelon M. Calcium phosphate adjuvanted allergens. Ann. Allergy 1985, 54(6):521-529.
69. Rock K.L., Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J. Immunol. 1996, 156(10):3721-3726.
70. Rooijen N.V., Nieuwmegen R.V. Use of liposomes as biodegradable and harmless adjuvants. Methods Enzymol. 1983, 93:83-95.
71. Salk J., Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195:834-846.
72. Sanchez A., Gupta R.K., Alonso M.J., Siber G.R., Langer R. Pulsed controlled-released system for potential use in vaccine delivery. J. Pharm. Sci. 1996, 85(6):547-552.
73. Sangmook L., Jae Wook L. Characterization and processing of biodegradable polymer blends of poly(lactic acid) with poly(butylene succinate adipate). Korea-Australia Rheol. J 2005, 17(2):71-77.
74. Sheets M.A., Unger B.A., Giggleman G.F., Tizard I.R. Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Mol. Biother. 1991, 3(1):41-45.
75. Shek P.N., Yung B.Y., Stanacev N.Z. Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation. Immunology 1983, 49(1):37-44.
76. Sinha V.R., Singla A.K., Wadhawan S., Kaushik R., Kumria R., Bansal K., Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int. J. Pharm. 2004, 274:1-33.
77. Sivakumar S.M., Sukumaran N., Nirmala L., Swarnalakshmi R., Anilbabu B., Siva L., Anbu J., Shanmugarajan T.S., Ravichandran V. Immunopotentiation of hepatitis B vaccine using biodegradable polymers as adjuvant. J. Microbiol. Immunol. Infect. 2010, 43(4):265-270.
78. Sjolander A., John Cox C., Ian Barr G. ISCOMs: an adjuvant with multiple functions. J. Leukoc. Biol. 1998, 64:713-723.
79. Stanley Davis S. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 2006, 24(Suppl.):S7-S10.
80. Tachihara K., Onishi H., Machida Y. Preparation of silver sulfadiazine containing spongy membranes of chitosan and chitin-chitosan mixture and their evaluation as burn wound dressings. Arch. Pract. Pharm. 1997, 57:159-167.
81. Tagliabue A., Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum. Vaccine 2008, 4(5):347-349.
82. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelop protein in ISCOMs. Nature 1990, 344:873-875.
83. Tiyaboonchai W., Nanteetip L. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int. J. Pharm. 2007, 329:142-149.
84. Tizard I.R., Carpenter R.H., McAnalley B.H., Kemp M.C. The biological activities of mannans and related complex carbohydrates. Mol. Biother. 1989, 1(6):290-296.
85. Tyrrel D.A., Heath T.D., Colley C.M., Ryman B.E. New aspects of liposomes. Biochim. Biophys. Acta 1976, 457:259-263.
86. Vander Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Coos Verhoef J., Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 2003, 21(13-14):1400-1408.
87. Vogel F.R. Adjuvants in perspective. Modulation of the Immune Response to Vaccine Antigens. Dev. Biol. Stand. 1998, vol. 92:241-248. Karger, Basel.
88. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12(5):387-400.
89. Walls R.S. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Med. 1977, 156:431-435.
90. Weibel R.E., McLean A., Woodhour A.F., Friedman A., Hilleman M.R. Ten-year follow up study for safety of adjuvant 65 influenza vaccine in man. Proc. Soc. Exp. Biol. Med. 1973, 143:1053-1056.
91. Winde G., Reers B., Notteberg H., Berns T., Meyer J., Bunte H. Clinical and functional results of abdominal rectopexy with absorbable mesh-graft for the treatment of complete rectal prolapse. Eur. J. Surg. 1993, 159(5):301-305.
92. Yong-Hong L., Marc Brown B., Stuart Jones A., Nazir T., Gary Martin P. The effects of poly vinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int. J. Pharm. 2005, 304:29-39.
93. Young S.L., Wilson M., Wilson S., Beagley K.W., Ward V., Barid M.A. Transcutaneous vaccination with virus-like particles. Vaccine 2006, 24:5406-5412.
94. Zheng L., Huang X.L., Fan Z., Borowski L., Wilson C.C., Rinaldo C.R. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res. Hum. Retroviruses 1999, 15(11):1011-1020.
95. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 2000, 12:163-171.
96. Zinkernagel R.M., Ehl S., Aichele P., Oehen S., Kündig T., Hengartner H. Antigen localization regulates immune responses in a dose and time dependent fashion: a geographical view of early immunity. Immunol. Rev. 1997, 156:199-209.